# UBE2W (Ubc16) [6His-tagged]

E2 – Ubiquitin Conjugating Enzyme

Alternate Names: FLJ11011

Cat. No.	62-0085-100
Lot. No.	30041

Quantity: 100 µg Storage: -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS



## **CERTIFICATE OF ANALYSIS Page 1 of 1**

## Background

The enzymes of the ubiquitylation pathway play a pivotal role in a number of cellular processes including the regulated and targeted proteasomal degradation of substrate proteins. Three classes of enzymes are involved in the process of ubiquitylation; activating enzymes (E1s), conjugating enzymes (E2s) and protein ligases (E3s). UBE2W is a member of the E2 conjugating enzyme family and cloning of the human gene was first described by Yin et al. (2006). UBE2W comprises 7 exons and there are two Nuclear Localisation Signals (NLS) located in the c-terminus of the UBC domain (Yin et al., 2006). Interaction of UBE2W with the human heteromeric RING E3 BRCA1-BARD1 has been demonstrated using yeast two-hybrid screening. UBE2W binds directly to the RING motif of BRCA-1 causing autoubiquitylation of BRCA1-BARD1 and monoubiquitylation of BRCA1 alone in vitro (Christensen et al., 2007). UBE2W also interacts with UBE1 and the E3 ligase FANCL to monoubiquitylate FANCD2 in vitro (Alpi et al., 2008)

#### **References:**

Alpi AF, Pace PE, Babu MM, Patel KJ (2008) Mechanistic insight into site-restricted monoubiquitination of FANCD2 by Ube2t, FANCL, and FANCI. *Mol Cell* **32**, 767-77.

Christensen DE, Brzovic PS, Klevit RE (2007) E2-BRCA1 RING interactions dictate synthesis of mono- or specific polyubiquitin chain linkages. *Nat Struct Mol Biol* **14**, 941-8.

Yin G, Ji C, Wu T, Shen Z, Xu X, Xie Y, Mao Y (2006) Cloning, characterization and subcellular localization of a gene encoding a human Ubiquitin-conjugating enzyme (E2) homologous to the Arabidopsis thaliana UBC-16 gene product. *Front Biosci* **11**, 1500-7.

# **Physical Characteristics**

Species: human

Source: E. coli expression

Quantity: 100 µg

Concentration: 1 mg/ml

**Formulation:** 50 mM HEPES pH 7.5, 150 mM sodium chloride, 2 mM dithiothreitol, 10% glycerol

Molecular Weight: ~22.2 kDa

Purity: >95% by InstantBlue™ SDS-PAGE

Stability/Storage: 12 months at -70°C; aliquot as required

# **Quality Assurance**

#### Purity:

4-12% gradient SDS-PAGE InstantBlue™ staining Lane 1: MW markers Lane 2: 1 μg His-UBE2W

kDa



#### Protein Sequence:

MGSSHHHHHHSSGLVPRGSHMASMTG GQQMGRGSMASMQTTGRRVEVWFPKRLQKEL LALQNDPPPGMTLNEKSVQNSITQWIVDMEGA PGTLYEGEKFQLLFKFSSRYPFDSPQVMFT GENIPVHPHVYSNGHICLSILTEDWSPALS VQSVCLSIISMLSSCKEKRRPPDNSFYVRTC NKNPKKTKWWYHDDTC

Tag (**bold text**): N-terminal His Protease cleavage site: Thrombin (<u>LVPR▼GS</u>) UBE2W (regular text): Start **bold italics** (amino acid residues 1-162) Accession number: NP\_001001481.1

#### Protein Identification:

Confirmed by mass spectrometry.

#### E2-Ubiquitin Thioester Loading Assay:

The activity of His-UBE2W was validated by loading E1 UBE1 activated ubiquitin onto the active cysteine of the His-UBE2W E2 enzyme via a transthiolation reaction. Incubation of the UBE1 and His-UBE2W enzymes in the presence of ubiquitin and ATP at 30°C was compared at two time points,  $T_0$  and  $T_{10}$  minutes. Sensitivity of the ubiquitin/His-UBE2W thioester bond to the reducing agent DTT was confirmed.



ORDERS / SALES SUPPORT International: +1-617-245-0003 US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233) Email: sales.support@ubiquigent.com UK HQ and TECHNICAL SUPPORT International: +44 (0) 1382 381147 (9AM-5PM UTC)

US/Canada: +1-617-245-0020 (9AM-5PM UTC) Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services. © Ubiquigent 2013. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.